本研究的目的是確定在局部晚期和不可切除的III期非小細胞肺癌參與者中， JNJ-90301900加入同時以鉑為基礎的雙聯化療加放射治療（ cCRT ），再加上鞏固免疫治療（ cIT ）是否可以提高客觀反應率（ ORR ；即研究期間最佳反應為完全反應或部分反應的參與者百分比）。

適應症：Carcinoma, Non-Small-Cell Lung

收案條件

Must be a candidate for standard of care (SOC) treatment of non small cell lung cancer (NSCLC) by concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation durvalumab treatment as determined by the investigator and per local guidelines at screening
Have a medical history of pathologically (histologically or cytologically) proven diagnosis of NSCLC within 3 months prior to enrollment/randomization
Have locally advanced unresectable stage III NSCLC according to the eighth edition lung cancer stage classification
Have at least 1 target lesion (primary lung lesion or involved lymph node\[s\]) per RECIST version 1.1 that is amenable to intratumoral and/or intranodal injection and intensity modulated radiation therapy (IMRT) as determined by the investigator at screening
Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1

Medical history of: (a) Primary immunodeficiency (b) Organ transplant that requires therapeutic immunosuppression
Any of the following within 3 months prior to enrollment/randomization: severe or unstable angina, myocardial infarction, clinically significant ventricular arrhythmias or heart failure New York heart association functional classification class III to IV
Another concurrent or prior primary malignancy within the last 36 months at informed consent
Known allergies, hypersensitivity, or intolerance to any ingredients of JNJ-90301900 crystalline solution, platinum-based doublet chemotherapy (ChT), or durvalumab
History of coagulation disorders, including: (a) Active bleeding diathesis or requirement for therapeutic anticoagulation or antiplatelet that cannot be interrupted or altered for JNJ-90301900 injection procedures, (b) Major thromboembolic events (for example, pulmonary embolism, cerebrovascular accident) within 3 months of enrollment or randomization

收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。

JNJ-90301900與放化療聯合治療非小細胞肺癌(NSCLC)的鞏固免疫療法研究